Aspect Biosystems
UBC Faculty of Applied Science
Aspect Biosystems is a UBC spin-off company that transformed a bold idea into an anchor company, here in British Columbia that is pioneering the advancement of 3D printing human tissue. Their deep tech platform combines microfluidics, AI-powered bioprinting, computational design, therapeutic cells, and advanced biomaterials to build functional, living tissues. These allogeneic tissue therapeutics are designed to replace, repair, or supplement biological functions, transforming disease treatment and improving health outcomes. With help from Innovation UBC, including technology licensing and patenting, along with venture building guidance and mentorship, the team refined their business model, validated product-market fit, and formalized their founding team, accelerating their path from academic research to viable venture. Aspect Biosystems’ technology supports medical research, therapeutic discovery, and regenerative medicine, saving lives and reshaping the future of healthcare.
Founders
Tamer Mohamed - CEO & Co-Founder
Simon Beyer - Co-Founder & Chief Technology Officer
Dr. Konrad Walus - Co-Founder
Sam Wadsworth - Co-Founder & Chief Scientific Officer
Timeline
2025 Raised $115M USD Series B venture financing to advance functional cures and strengthen
Aspect’s tissue therapeutic platform (Learn more)
2024 $200M partnership with Government of Canada and BC to accelerate truly disease-
modifying treatments and functional cures for serious metabolic and endocrine diseases
(Learn more)
2023 $2.675B Novo Nordisk partnership to develop bioprinted tissue therapeutics for diabetes
and obesity (largest-ever material partnership for a BC biotech company) (Learn more)
$3.7M from PacifiCan to broaden the application of its bioprinting technology for
therapeutic development, expand global partnerships, and scale manufacturing systems
(Learn more)
2020 Raised $20M USD Series A venture financing to advance its leading platform for 3D
bioprinting of human tissue (Learn more)
2019 $2.2M collaboration project (immuno-oncology R&D)
$148K government grant (Innovate BC ignitie program) focused on developing machine-
learning based technology to improve 3D printing quality (Learn more)
2018 $1M investment from Genome BC industry innovation grant for commercialization
initiatives and the platform technology development (Learn more)
$2.7M government funding (Western Innovation Initiative) to advance the therapeutic
potential of bioprinting technology (Learn more)
2014 UBC license completed
